Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

KX-826, Breezula, PP405, and Stemson are potential future treatments for hair loss, with varying timelines and mechanisms like blocking DHT and stem cell activation. Users express skepticism about the timeline and mention current options like hair transplants and minoxidil.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

Severe balding negatively impacts self-esteem and quality of life. Treatments discussed include hair transplant, hair system, and embracing baldness.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Alfatradiol is suggested as another potential solution.

Male pattern baldness is linked to health risks and should be treated medically. Finasteride is effective and should be insurance-covered.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The user received hormone test results showing normal estradiol and testosterone levels, low SHBG, and normal free androgen index. They are considering starting finasteride but are concerned due to being slightly overweight.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

After stopping finasteride, the user retained hair without noticeable balding, suggesting an unusual reaction to the medication. The user initially experienced rapid hair loss and itchiness, possibly due to male pattern baldness, but maintained hair stability after tapering off finasteride.

A person feels intense shame and self-hatred due to baldness and poor self-image, affecting their confidence and social interactions. Suggestions include therapy, exercise, braces, hair transplants, and using finasteride.

Finding treatments for regrowth on the hairline which have not been successful so far, with suggestions of maintaining what they currently have and considering a hair transplant as an option.

A user plans to undergo a temporary MtF transformation to regrow hair, using estrogen, RU58841, and Dutasteride, then revert with testosterone. Many users criticize the plan, suggesting alternatives like hair transplants, and emphasize that estrogen is not a reliable solution for hair regrowth.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

A 46-year-old man is using minoxidil, finasteride, and derma rolling for hair regrowth but is unsure of the results and considering a hair transplant. Many suggest he looks good bald and recommend continuing treatment or trying scalp micropigmentation.

A 22-year-old male experiencing hair thinning is considering starting finasteride but is concerned about potential side effects and hereditary factors. While waiting to access finasteride, he plans to use pumpkin seed oil, saw palmetto, biotin, and vitamins, and is advised to check blood levels before starting treatment.

A 21-year-old is experiencing hair loss and is unsure whether to choose minoxidil or finasteride. They prefer oral treatments and are leaning towards finasteride despite concerns about side effects and family opposition.

A 20-year-old with no signs of hair loss is considering finasteride or dutasteride due to family history of baldness. Advice given is to monitor hair and start treatment only if thinning occurs.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

A 51-year-old shared progress on hair regrowth using topical Minoxidil and Finasteride over four months, noting significant improvement and plans for future hair transplants. The user emphasized the benefits of modern treatments and societal changes in attitudes towards hair loss.

The user switched from finasteride to dutasteride after 1.5 years without results. They are hopeful the new treatment will work.

A user who was able to get dutasteride for free with their insurance, and another user mentioning that finasteride is only covered if it is used for medical reasons.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.